Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience

J Cardiovasc Med (Hagerstown). 2018 Feb;19(2):75-77. doi: 10.2459/JCM.0000000000000611.

Authors

Felice Gragnano¹, Francesco Natale, Claudia Concilio, Fabio Fimiani, Arturo Cesaro, Simona Sperlongano, Mario Crisci, Giuseppe Limongelli, Raffaele Calabrò, Mariagiovanna Russo, Enrica Golia, Paolo Calabrò

Affiliation

¹ Division of Cardiology, Department of Cardiothoracic and Respiratory Sciences, University of Campania 'Luigi Vanvitelli', A.O. dei Colli Monaldi Hospital, Naples, Italy.

PMID: 29251697
DOI: 10.2459/JCM.0000000000000611

No abstract available

Publication types

Letter

MeSH terms

Cardiovascular Diseases / prevention & control*
Cholesterol, LDL / blood
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypercholesterolemia / complications
Hypercholesterolemia / drug therapy*
Italy
Male
Medication Adherence / statistics & numerical data*
Middle Aged
PCSK9 Inhibitors*
Prospective Studies
Risk Factors

Substances

Cholesterol, LDL
Hydroxymethylglutaryl-CoA Reductase Inhibitors
PCSK9 Inhibitors